<DOC>
	<DOCNO>NCT00996047</DOCNO>
	<brief_summary>RATIONALE : Studying sample bone marrow blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This research study look bone marrow blood sample patient leukemia hematopoietic cancer .</brief_summary>
	<brief_title>S9007 , Study Bone Marrow Blood Samples From Patients With Leukemia Other Hematopoietic Cancers</brief_title>
	<detailed_description>Primary objective : * Maintain expand database cytogenetic information leukemia patient . Other objective fund permit : - Determine frequency prognostic significance cytogenetic abnormality bone marrow peripheral blood cell patient leukemia prior treatment various time treatment undergoing treatment companion clinical trial . - Correlate presence cytogenetic feature clinical , pathophysiological , cellular , molecular characteristic patient . - Provide quality control Southwest Oncology Group cytogenetic data . OUTLINE : Bone marrow and/or peripheral blood sample patient specific treatment protocol leukemia analyze cytogenetic abnormality . Samples patient chronic lymphocytic leukemia ( CLL ) analyze trisomy 12 fluorescence situ hybridization conventional cytogenetics . PROJECTED ACCRUAL : Approximately 2,500 patient ( 1,200 first-line acute myeloid leukemia [ AML ] , 500 first-line acute lymphoblastic leukemia [ ALL ] , 200 relapse AML , 125 chronic phase chronic myelogenous leukemia [ CML ] , 100 accelerate phase blastic phase CML , 250 hairy cell leukemia , 125 relapse ALL CLL ) accrue study within 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Registered one follow Southwest Oncology Group treatment protocol : SWOG8326 , SWOG8600 , SWOG8612 , SWOG9034 , SWOG9108 , OR new leukemia protocol approve 1990 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm</keyword>
</DOC>